Blockchain Registration Transaction Record

Onco-Innovations Hits 99.3% Purity in Drug Scale-Up, Appoints New CFO

Onco-Innovations completes 300-gram scale-up of A83B4C63 with 99.3% purity for ONC010 drug candidate, appoints Dave Antony as CFO. Learn about the PNKP inhibitor program and next steps.

This milestone is significant because it demonstrates that Onco-Innovations' ONC010 drug candidate can be manufactured at scale with high purity and consistency, a critical step toward clinical trials and eventual commercialization. For investors and patients, it signals progress in developing a potential new treatment for solid tumours, addressing a major unmet need in oncology. The appointment of a new CFO also strengthens the company's financial leadership as it moves toward First-in-Human studies.